“But I'm going to rely heavily on a team that has shown that they can actually do that and do that in pretty difficult circumstances already. And continue to be able to drive the business in that, you know, seven, eight, 9% range here.”

In context

“s we sit still here. I'd be curious if you see anything that we need to sort of be aware of over the next twelve, maybe twelve to eighteen months. And then my second question has to do with structural heart. Looks like you've multiple products, we'll call them multiple shots, and goal is keeping that growth rate going nicely. Anything you want to call out in particular or anything we should be looking at for the upcoming medical meetings? Thanks. Robert Ford: Sure. Regarding EPD, I mean, I think this team is incredibly resilient and I get that there's some concern about geopolitics going forward, but let's face it, Joanne. I mean, there's been macro challenges at least since I've been in this role for the last five years. And so yes. We gotta pay attention to them. Yes. We gotta navigate. But I'm going to rely heavily on a team that has shown that they can actually do that and do that in pretty difficult circumstances already. And continue to be able to drive the business in that, you know, seven, eight, 9% range here. So yeah, it's we gotta be mindful of it, but this is a team that on at least in these markets, have proved to be very resilient, have deep connections in the market, deep relationships, you know, clinical, distribution wise. So, and now that we're bringing our biosimilar portfolio into these markets, biosimilars are now the fastest growing generic kind segment. I feel good about this business. I think, you know, the idea of bringing this differentiated portfolio in a team that has done extremely well in navigating all of this. I think we've got, you know, also strong aspirations for this business. So, yeah, we'll keep an eye on out, but I don't think that, you know, it's something completely new for us or this business. We operate in 160 countries. We're truly a global company. So we will”